US drugmaker Merck & Co. (MSD) has entered into a global license agreement to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from Chinese biotechnology company LaNova Medicines.
Quantro Therapeutics, which focuses on transcription factors targeting cancer treatments, announced that it has reached a key milestone in its joint R&D program with Boehringer Ingelheim.
Swiss drugmaker Novartis agreed to acquire Mariana Oncology, a US biotechnology company based in Watertown, Massachusetts, that develops novel radioligand therapies (RLTs) for the treatment of cancer.
Japan’s Ono Pharmaceutical agreed to acquire US cancer-therapy company Deciphera Pharmaceuticals for approximately $2.4 billion. Deciphera focuses on innovative cancer therapeutics, and specializes in kinase biology.
Danish drugmaker Genmab has agreed to buy privately-owned US biotechnology company ProfoundBio for $1.8 billion. ProfoundBio develops novel ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors.
